Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk.
Hans-Peter HartungJan MaresSven G MeuthThomas BergerPublished in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2021)
Keyphrases